{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:46:56Z","timestamp":1792597616425,"version":"4.5.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"DOI":"10.1007\/s11239-025-03159-2","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T19:33:13Z","timestamp":1755631993000},"page":"196-209","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Measurement of plasma direct oral anticoagulants concentrations in real-world clinical and laboratory settings on a 24\/7 basis: a 10-year experience"],"prefix":"10.1007","volume":"59","author":[{"given":"Agnieszka","family":"Kotnis-G\u0105ska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agata","family":"Trawi\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"El\u017cbieta","family":"Broniatowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u0142gorzata","family":"Konieczy\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anetta","family":"Undas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Wypasek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,19]]},"reference":[{"key":"3159_CR1","doi-asserted-by":"crossref","unstructured":"Barnes GD, Ageno W, Ansell J et al (2015) Subcommittee on the Control of Anticoagulation of the International Society on Thrombosis and Haemostasis. Recommendation on the nomenclature for oral anticoagulants: communication from the SSC of the ISTH. J Thromb Haemost 13:1154-6. https:\/\/doi.10.1111\/jth.12969","DOI":"10.1111\/jth.12969"},{"key":"3159_CR2","doi-asserted-by":"publisher","unstructured":"Lippi G, Mattiuzzi C, Cervellin G et al (2017) Direct oral anticoagulants: analysis of worldwide use and popularity using Google trends. Ann Transl Med 5(322). https:\/\/doi.org\/10.21037\/atm.2017.06.65","DOI":"10.21037\/atm.2017.06.65"},{"key":"3159_CR3","doi-asserted-by":"publisher","unstructured":"Favaloro EJ, Pasalic L, Lippi G (2020) Oral anticoagulation therapy: an update on usage, costs and associated risks. Pathology 52:736\u2013741. https:\/\/doi.org\/10.1016\/j.pathol.2020.05.006","DOI":"10.1016\/j.pathol.2020.05.006"},{"key":"3159_CR4","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1093\/europace\/euab065","volume":"23","author":"J Steffel","year":"2021","unstructured":"Steffel J, Collins R, Antz M et al (2021) 2021 European heart rhythm association practical guide on the use of Non-Vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace 23:1612\u20131676. https:\/\/doi.org\/10.1093\/europace\/euab065","journal-title":"Europace"},{"key":"3159_CR5","doi-asserted-by":"crossref","unstructured":"Douxfils J, Ageno W, Samama CM et al (2018) Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians. J Thromb Haemost 16:209\u2013219. https:\/\/doi.org\/10.1111\/jth.13912.","DOI":"10.1111\/jth.13912"},{"key":"3159_CR6","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.thromres.2024.04.005","volume":"237","author":"N Gendron","year":"2024","unstructured":"Gendron N, Billoir P, Siguret V et al (2024) Is there a role for the laboratory monitoring in the management of specific antidotes of direct oral anticoagulants? Thromb Res 237:171\u2013180. https:\/\/doi.org\/10.1016\/j.thromres.2024.04.005","journal-title":"Thromb Res"},{"key":"3159_CR7","doi-asserted-by":"crossref","unstructured":"Harenberg J, Du S, Wehling M et al (2016) Measurement of dabigatran, rivaroxaban and apixaban in samples of plasma, serum and urine, under real life conditions. An international study. Clin Chem Lab Med 54:275\u2013\u200983. https:\/\/doi.10.1515\/cclm-2015-0389","DOI":"10.1515\/cclm-2015-0389"},{"key":"3159_CR8","doi-asserted-by":"publisher","unstructured":"Van der Linden L, Hias J, Vanassche T (2022) The value and limitations of new oral anticoagulant plasma level assessments. Eur Heart J Suppl 24(A32\u2013A41). https:\/\/doi.org\/10.1093\/eurheartj\/suab153","DOI":"10.1093\/eurheartj\/suab153"},{"key":"3159_CR9","doi-asserted-by":"crossref","unstructured":"Eikelboom JW, Quinlan DJ, Hirsh J (2017) Laboratory monitoring of non-vitamin K antagonist oral anticoagulant use in patients with atrial fibrillation: A review. JAMA Cardiol 2:566\u2013574. https:\/\/doi.10.1001\/jamacardio.2017.0364","DOI":"10.1001\/jamacardio.2017.0364"},{"key":"3159_CR10","doi-asserted-by":"crossref","unstructured":"Diener HC, Sacco RL, Easton JD et al (2019) Dabigatran for prevention of stroke after embolic stroke of undetermined source. N Engl J Med 380:1906\u20131917. https:\/\/doi.10.1056\/NEJMoa1813959","DOI":"10.1056\/NEJMoa1813959"},{"key":"3159_CR11","doi-asserted-by":"crossref","unstructured":"Douxfils J, Adcock DM, Bates SM et al (2021) 2021 update of the international council for standardization in haematology recommendations for laboratory measurement of direct oral anticoagulants. Thromb Haemost 121:1008\u20131020. https:\/\/doi.10.1055\/a-1450-8178","DOI":"10.1055\/a-1450-8178"},{"key":"3159_CR12","doi-asserted-by":"crossref","unstructured":"Joglar JA, Chung MK, Armbruster AL et al (2024) 2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 149:e1-e156. https:\/\/doi.10.1161\/CIR.0000000000001193","DOI":"10.1161\/CIR.0000000000001207"},{"key":"3159_CR13","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.thromres.2021.08.010","volume":"206","author":"T Cavaillez","year":"2021","unstructured":"Cavaillez T, Weinmann L, Mouton C et al (2021) A retrospective study of indications and consequences of monitoring direct oral anticoagulant plasma concentrations on patient care in a university hospital: the Retro-AOD study. Thromb Res 206:76\u201383. https:\/\/doi.org\/10.1016\/j.thromres.2021.08.010","journal-title":"Thromb Res"},{"key":"3159_CR14","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s11239-018-1643-0","volume":"45","author":"A Rottenstreich","year":"2018","unstructured":"Rottenstreich A, Zacks N, Kleinstern G et al (2018) Direct-acting oral anticoagulant drug level monitoring in clinical patient management. J Thromb Thrombolysis 45:543\u2013549. https:\/\/doi.org\/10.1007\/s11239-018-1643-0","journal-title":"J Thromb Thrombolysis"},{"key":"3159_CR15","doi-asserted-by":"crossref","unstructured":"Bavalia R, Veenhuizen JE, Hengeveld RCC et al (2021) Direct oral anticoagulant blood level monitoring in daily practice. Thrombosis Update 3:1\u20136. https:\/\/doi.10.1016\/j.tru.2021.100049","DOI":"10.1016\/j.tru.2021.100049"},{"key":"3159_CR16","doi-asserted-by":"crossref","unstructured":"Winther-Larsen A, Hvas AM (2019) Clinical impact of direct oral anticoagulant measuring in a real-life setting. Thromb Res 175:40\u201345. https:\/\/doi.10.1016\/j.thromres.2019.01.016","DOI":"10.1016\/j.thromres.2019.01.016"},{"key":"3159_CR17","doi-asserted-by":"crossref","unstructured":"Denny NDR, Keighley L, Siganporia Z et al (2019) A level-headed approach to measuring direct oral anticoagulants: A 2-year retrospective analysis of DOAC levels from a tertiary UK centre. Int J Lab Hematol 41:200\u2013207. https:\/\/doi.10.1111\/ijlh.12944","DOI":"10.1111\/ijlh.12944"},{"key":"3159_CR18","doi-asserted-by":"crossref","unstructured":"Car\u00e9 W, Foissaud V, Lefeuvre L et al (2021) Direct oral anticoagulant plasma level measurement in clinical practice: A French single-institution retrospective study. Thromb Res 200:83\u201386. https:\/\/doi.10.1016\/j.thromres.2021.01.021","DOI":"10.1016\/j.thromres.2021.01.021"},{"key":"3159_CR19","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s11239-018-1793-0","volume":"47","author":"TM Gu","year":"2019","unstructured":"Gu TM, Garcia DA, Sabath DE (2019) Assessment of direct oral anticoagulant assay use in clinical practice. J Thromb Thrombolysis 47:403\u2013408. https:\/\/doi.org\/10.1007\/s11239-018-1793-0","journal-title":"J Thromb Thrombolysis"},{"key":"3159_CR20","doi-asserted-by":"crossref","unstructured":"Chin PKL, McNeill R, Lee HK et al (2020) Routine Therapeutic Drug Monitoring of Dabigatran: Experience at a Tertiary Center. The Drug Monit 42:468\u2013472. https:\/\/doi.10.1097\/FTD.0000000000000713","DOI":"10.1097\/FTD.0000000000000713"},{"key":"3159_CR21","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/ijlh.12654","volume":"39","author":"C Wright","year":"2017","unstructured":"Wright C, Brown R, Cuker A (2017) Laboratory measurement of the direct oral anticoagulants: indications and impact on management in clinical practice. Int J Lab Hematol 39:31\u201336. https:\/\/doi.org\/10.1111\/ijlh.12654","journal-title":"Int J Lab Hematol"},{"key":"3159_CR22","doi-asserted-by":"crossref","unstructured":"Zalewski J, Rychlak R, G\u00f3ralczyk T et al (2014) Rivaroxaban concentration in patients with deep vein thrombosis who reported thrombus progression or minor hemorrhagic complications: first Polish experience. Pol Arch Intern Med 124:553-5. https:\/\/doi.10.20452\/pamw.2470","DOI":"10.20452\/pamw.2470"},{"key":"3159_CR23","doi-asserted-by":"publisher","first-page":"487","DOI":"10.20452\/pamw.2415","volume":"124","author":"U Czubek","year":"2014","unstructured":"Czubek U, G\u00f3ralczyk T, Zalewski J et al (2014) Monitoring of anticoagulant effects of Dabigatran in everyday practice: first experience in 32 Polish patients. Pol Arch Intern Med 124:487\u2013489. https:\/\/doi.org\/10.20452\/pamw.2415","journal-title":"Pol Arch Intern Med"},{"key":"3159_CR24","doi-asserted-by":"crossref","unstructured":"G\u00f3ralczyk T, Papuga-Szela E, \u017buk J et al (2018) Measurement of apixaban concentrations in real\u2013world clinical and laboratory settings: the first Polish experience. Pol Arch Intern Med 128:324\u2013326. https:\/\/doi.10.20452\/pamw.4265","DOI":"10.20452\/pamw.4265"},{"key":"3159_CR25","unstructured":"Core RT (2021) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL https:\/\/www.R-project.org\/"},{"key":"3159_CR26","doi-asserted-by":"crossref","unstructured":"Hart RG, Diener HC, Coutts SB et al (2014) Cryptogenic Stroke\/ESUS International Working Group. Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurol. 13:429\u2013\u200938. https:\/\/doi.10.1016\/S1474-4422(13)70310-7","DOI":"10.1016\/S1474-4422(13)70310-7"},{"key":"3159_CR27","doi-asserted-by":"crossref","unstructured":"Witte KK, Tsivgoulis G, Reynolds MR et al (2021) Burden of oral anticoagulation in embolic stroke of undetermined source without atrial fibrillation. BMC Cardiovasc Disord. 21:160. https:\/\/doi.10.1186\/s12872-021-01967-x","DOI":"10.1186\/s12872-021-01967-x"},{"key":"3159_CR28","doi-asserted-by":"publisher","first-page":"107189","DOI":"10.1016\/j.clineuro.2022.107189","volume":"215","author":"S Chen","year":"2022","unstructured":"Chen S, Cai D, Lai Y et al (2022) Dabigatran versus aspirin for stroke prevention after cryptogenic stroke with patent foramen ovale: A prospective study. Clin Neurol Neurosurg 215:107189. https:\/\/doi.org\/10.1016\/j.clineuro.2022.107189","journal-title":"Clin Neurol Neurosurg"},{"key":"3159_CR29","doi-asserted-by":"publisher","first-page":"845","DOI":"10.54029\/2022fma","volume":"27","author":"M Tajmirriahi","year":"2022","unstructured":"Tajmirriahi M, Sarafi R, Khorvash F, Saadatnia M (2022) The effect of Rivaroxaban vs aspirin on stroke recurrence among patients with history of cryptogenic stroke and left atrial cardiomyopathy: an analytical cross-sectional study. Neurol Asia 27:845\u2013849. https:\/\/doi.org\/10.54029\/2022fma","journal-title":"Neurol Asia"},{"key":"3159_CR30","doi-asserted-by":"crossref","unstructured":"Hart RG, Sharma M, Mundl H et al (2018) Rivaroxaban for stroke prevention after embolic stroke of undetermined source. N Engl J Med. 378:2191\u2013201. https:\/\/doi.10.1056\/NEJMoa1802686","DOI":"10.1056\/NEJMoa1802686"},{"key":"3159_CR31","unstructured":"Diener HC, Sacco RL, Easton JD et al (2019) RE-SPECT ESUS Steering Committee and Investigators. Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source. N Engl J Med. 380:1906\u20131917. https:\/\/doi.10.1056\/NEJMoa1813959"},{"key":"3159_CR32","doi-asserted-by":"crossref","unstructured":"Kamel H, Longstreth WT Jr, Tirschwell DL et al (2024) ARCADIA Investigators. Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy: The ARCADIA Randomized Clinical Trial. JAMA. 331:573\u2013581. https:\/\/doi.10.1001\/jama.2023.27188","DOI":"10.1001\/jama.2024.6855"},{"key":"3159_CR33","doi-asserted-by":"publisher","unstructured":"Touz\u00e9 E, Gruel Y, Gouin-Thibault I et al (2018) Intravenous thrombolysis for acute ischaemic stroke in patients on direct oral anticoagulants. Eur J Neurol 25(747\u2013e52). https:\/\/doi.org\/10.1111\/ene.13582","DOI":"10.1111\/ene.13582"},{"key":"3159_CR34","doi-asserted-by":"crossref","unstructured":"Levine GN, McEvoy JW, Fang JC, American Heart Association Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; and Stroke Council (2022). Management of Patients at Risk for and With Left Ventricular Thrombus: A Scientific Statement From the American Heart Association. Circulation 146:e205-e223. https:\/\/doi.10.1161\/CIR.0000000000001092","DOI":"10.1161\/CIR.0000000000001092"},{"key":"3159_CR35","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s12325-022-02333-9","volume":"40","author":"S Ballestri","year":"2023","unstructured":"Ballestri S, Romagnoli E, Arioli D et al (2023) Risk and management of bleeding complications with direct oral anticoagulants in patients with atrial fibrillation and venous thromboembolism: a narrative review. Adv Ther 40:41\u201366. https:\/\/doi.org\/10.1007\/s12325-022-02333-9","journal-title":"Adv Ther"},{"key":"3159_CR36","doi-asserted-by":"publisher","unstructured":"Powers WJ, Rabinstein AA, Ackerson T et al (2019) Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American heart association\/american stroke association. Stroke 50:e344\u2013e418. https:\/\/doi.org\/10.1161\/STR.0000000000000211","DOI":"10.1161\/STR.0000000000000211"},{"key":"3159_CR37","doi-asserted-by":"crossref","unstructured":"Meinel TR, Branca M, De Marchis GM et al (2021) Investigators of the Swiss Stroke Registry. Prior anticoagulation in patients with ischemic stroke and atrial fibrillation. Ann Neurol 89:42\u201353. https:\/\/doi.10.1002\/ana.25917","DOI":"10.1002\/ana.25917"},{"key":"3159_CR38","doi-asserted-by":"publisher","first-page":"579","DOI":"10.20452\/pamw.3769","volume":"126","author":"P Mazur","year":"2016","unstructured":"Mazur P, Darocha T, Filip G et al (2016) Idarucizumab for Dabigatran reversal in patients with atrial fibrillation undergoing emergency surgery for acute aortic syndrome. Pol Arch Intern Med 126:579\u2013581. https:\/\/doi.org\/10.20452\/pamw.3769","journal-title":"Pol Arch Intern Med"},{"key":"3159_CR39","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1093\/europace\/euy220","volume":"21","author":"SJ van der Wall","year":"2019","unstructured":"van der Wall SJ, van Rein N, van den Bemt B et al (2019) Performance of Idarucizumab as antidote of Dabigatran in daily clinical practice. Europace 21:414\u2013420. https:\/\/doi.org\/10.1093\/europace\/euy220","journal-title":"Europace"},{"key":"3159_CR40","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.thromres.2024.04.005","volume":"237","author":"N Gendron","year":"2024","unstructured":"Gendron N, Billoir P, Siguret V, French Society on Thrombosis and Haemostasis (2024) Is there a role for the laboratory monitoring in the management of specific antidotes of direct oral anticoagulants? Thromb Res 237:171\u2013180. https:\/\/doi.org\/10.1016\/j.thromres.2024.04.005","journal-title":"Thromb Res"},{"key":"3159_CR41","doi-asserted-by":"crossref","unstructured":"Kazimierczyk E, D\u0105browska M, Gierlotka M et al (2024) The use of andexanpha in the Polish setting: An interdisciplinary protocol. Expert consensus statement of the Polish Cardiac Society. Polish Heart Journal 82:123\u2013139. https:\/\/doi.10.33963\/v.kp.98059","DOI":"10.33963\/v.kp.98059"},{"key":"3159_CR42","doi-asserted-by":"crossref","unstructured":"Seiffge DJ, Traenka C, Polymeris A et al (2017) Feasibility of rapid measurement of rivaroxaban plasma levels in patients with acute stroke. J Thromb Thrombolysis 43:112\u2013116. https:\/\/doi.10.1007\/s11239-016-1431-7","DOI":"10.1007\/s11239-016-1431-7"},{"key":"3159_CR43","doi-asserted-by":"crossref","unstructured":"Dincq AS, Lessire S, Pirard G et al (2018) Reduction of the turn-around time for the measurement of rivaroxaban and apixaban: Assessment of the performance of a rapid centrifugation method. Int J Lab Hematol 40:e105-e108. https:\/\/doi.10.1111\/ijlh.12870","DOI":"10.1111\/ijlh.12870"},{"key":"3159_CR44","doi-asserted-by":"crossref","unstructured":"Yu J, Zhu G, Cui K et al (2024) Comparison of the speed and quality of innovative and traditional pneumatic tube system transport outside of an emergency laboratory. Heliyon 10:e31511. https:\/\/doi.10.1016\/j.heliyon.2024.e31511","DOI":"10.1016\/j.heliyon.2024.e31511"},{"key":"3159_CR45","doi-asserted-by":"crossref","unstructured":"Plebani M, Nichols JH, Luppa PB et al (2024) Point-of-care testing: state-of-the art and perspectives. Clin Chem Lab Med 63:35\u201351. https:\/\/doi.10.1515\/cclm-2024-0675","DOI":"10.1515\/cclm-2024-0675"},{"key":"3159_CR46","doi-asserted-by":"crossref","unstructured":"Merrelaar AE, B\u00f6gl MS, Buchtele N et al (2022) Performance of a Qualitative Point-of-Care Strip Test to Detect DOAC Exposure at the Emergency Department: A Cohort-Type Cross-Sectional Diagnostic Accuracy Study. Thromb Haemost. 122:1723\u20131731. https:\/\/doi.10.1055\/s-0042-1750327","DOI":"10.1055\/s-0042-1750327"},{"key":"3159_CR47","doi-asserted-by":"crossref","unstructured":"Martini A, Harenberg J, Bauersachs R et al (2021) Detection of Direct Oral Anticoagulants in Patient Urine Samples by Prototype and Commercial Test Strips for DOACs - A Systematic Review and Meta-analysis. TH Open. 5:e438-e448. https:\/\/doi.10.1055\/s-0041-1732437","DOI":"10.1055\/s-0041-1732437"},{"key":"3159_CR48","doi-asserted-by":"crossref","unstructured":"Papageorgiou L, Hetjens S, Fareed J et al (2023) Comparison of the DOAC Dipstick Test on Urine Samples With Chromogenic Substrate Methods on Plasma Samples in Outpatients Treated With Direct Oral Anticoagulants. Clin Appl Thromb Hemost. 29:10760296231179684. https:\/\/doi.10.1177\/10760296231179684","DOI":"10.1177\/10760296231179684"},{"key":"3159_CR49","doi-asserted-by":"crossref","unstructured":"Rosovsky RP, Sanfilippo KM, Wang TF et al (2020) Anticoagulation practice patterns in COVID-19: A global survey. Res Pract Thromb Haemost 4: 969\u2013983. https:\/\/doi.10.1002\/rth2.12414","DOI":"10.1002\/rth2.12414"},{"key":"3159_CR50","doi-asserted-by":"crossref","unstructured":"Kolanko E, Senderek T, Prokop-Staszecka A et al (2021) Thromboprophylaxis in hospitalized COVID-19 patients: the efficacy and safety of the approved hospital protocol. Pol Arch Intern Med 131:16102. https:\/\/doi.10.20452\/pamw.161","DOI":"10.20452\/pamw.16102"},{"key":"3159_CR51","doi-asserted-by":"crossref","unstructured":"Adcock DM, Gosselin RC (2017) The danger of relying on the APTT and PT in patients on DOAC therapy, a potential patient safety issue. Int J Lab Hematol. 39: 37\u201340. https:\/\/doi.10.1111\/ijlh.12658. PMID: 28447415","DOI":"10.1111\/ijlh.12658"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-025-03159-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-025-03159-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-025-03159-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T13:42:11Z","timestamp":1770644531000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-025-03159-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,19]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["3159"],"URL":"https:\/\/doi.org\/10.1007\/s11239-025-03159-2","relation":{},"ISSN":["1573-742X"],"issn-type":[{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,19]]},"assertion":[{"value":"18 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A. Undas declares lecture honoraria from Bayer, Boehringer Ingelheim, and Pfizer and support for travel from Bayer and Pfizer. The other authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}